Welcome to our dedicated page for Relay Therapeutics news (Ticker: RLAY), a resource for investors and traders seeking the latest updates and insights on Relay Therapeutics stock.
Relay Therapeutics, Inc. develops clinical-stage small molecule precision medicines for cancer and genetic disease. The company uses its Dynamo® platform, which combines computational and experimental approaches to drug protein targets that have been intractable or inadequately addressed.
Recurring RLAY news centers on zovegalisib (RLY-2608), a mutant-selective PI3Kα inhibitor studied in HR+/HER2- metastatic breast cancer and PI3Kα-driven vascular anomalies. Company updates also cover pipeline programs for NRAS-driven solid tumors and Fabry disease, clinical and regulatory data presentations, operating results, capital-structure matters, license or collaboration agreements, and governance developments.
Relay Therapeutics (Nasdaq: RLAY) has appointed Dr. Patrick Riley as the senior vice president of artificial intelligence, enhancing its computational strength in drug discovery. With 15 years of experience from Google, Dr. Riley will spearhead a computational team focused on applying AI to drug development. His expertise in machine learning and data science is expected to strengthen Relay's innovative approach, particularly following its recent acquisition of ZebiAI. The company aims to tackle challenging protein targets to deliver transformative therapies.
Relay Therapeutics (Nasdaq: RLAY) will participate in a fireside chat at the Bank of America 2021 Health Care Conference on May 11, 2021, at 8:45 a.m. ET. This event can be accessed live via Relay’s Investor page, with an archived replay available for 24 hours post-event, until August 13, 2021. Relay Therapeutics is a clinical-stage precision medicines company utilizing its innovative Dynamo™ platform to advance small molecule discoveries for targeted oncology and genetic diseases.
Relay Therapeutics announced the appointments of Tara O'Meara as Senior VP of Clinical Development Operations and Dr. Charles Ferté as VP, Global Medical Lead for RLY-4008. Both bring extensive experience in drug development, aimed at enhancing Relay's clinical capabilities. O'Meara has over a decade of experience in rare genetic diseases and oncology, while Dr. Ferté has 15 years in oncology R&D, including roles at AstraZeneca. This leadership expansion is expected to strengthen Relay's drug pipeline as they continue developing therapies for critical conditions.
Relay Therapeutics has announced its acquisition of ZebiAI for $85 million, comprising $20 million in cash and $65 million in stock. This acquisition aims to enhance Relay’s Dynamo™ platform, integrating ZebiAI's extensive experimental data and machine learning models to accelerate drug discovery. The deal allows for additional milestone payments up to $85 million and a 10% share of future collaboration revenues, capped at $100 million. Relay anticipates this acquisition will strengthen its position in the biotech sector and support its operational plans into 2024.
Relay Therapeutics reported strong advancements in 2020, including two programs, RLY-1971 and RLY-4008, entering clinical development. The company raised $460 million in its IPO and secured a collaboration with Genentech for RLY-1971, boosting its finances to approximately $678.1 million. Net income reached $35.3 million in Q4 2020, a significant improvement over the previous year’s loss. R&D expenses rose to $32.1 million in Q4 2020, reflecting increased clinical trial activity. Relay emphasized 2021 as a pivotal year for executing its drug discovery mission.
RLY-4008, a novel oral small molecule inhibitor of FGFR2 developed by Relay Therapeutics, shows promising preclinical results against FGFR2-altered cancers. The drug exhibits strong activity against known resistance mutations and demonstrates efficacy in both cellular and in vivo preclinical models. The data will be presented at the AACR Annual Meeting scheduled for April 10-15 and May 17-21, 2021. Initial clinical data for RLY-4008 is expected later in 2021. The company aims to advance treatment options for patients with advanced or metastatic solid tumors.
Relay Therapeutics (Nasdaq: RLAY) will participate in a fireside chat at the Guggenheim Healthcare Talks 2021 Oncology Day on February 11, 2021, at 3:30 p.m. ET. The chat will be streamed live and can be accessed on the Investor page of Relay's website. An archived replay will be available for one year after the event. Relay Therapeutics focuses on precision medicine and utilizes its Dynamo platform to innovate drug discovery, particularly in targeted oncology. For more details, visit their website or follow them on Twitter.
Relay Therapeutics (Nasdaq: RLAY) will present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 4:30 p.m. ET. The presentation will be available via a live webcast on Relay’s website, with an archived replay accessible for 30 days post-event. The company focuses on innovative drug discovery using its Dynamo platform, enhancing small molecule therapies targeting oncology. Relay Therapeutics aims to revolutionize the approach to previously challenging protein targets by utilizing advanced experimental and computational techniques.
Relay Therapeutics has entered a global collaboration with Genentech to develop RLY-1971, a SHP2 inhibitor, with an upfront payment of $75 million. Additional payments could total $25 million and up to $695 million in milestone payments. Relay retains rights to combine RLY-1971 with other therapies. The collaboration aims to enhance treatment options for cancer patients, especially targeting KRAS G12C mutations. The company states this partnership secures operational funds through 2024. A conference call discussing the details is scheduled for 8:00 a.m. ET.
Relay Therapeutics, Inc. (Nasdaq: RLAY) reported its third quarter 2020 financial results, noting significant progress following its IPO in July. The company has approximately $713 million in cash, expected to fund operations into 2023. R&D expenses increased to $24 million, largely due to higher personnel costs and clinical trial support. General and administrative expenses rose to $12 million, reflecting increased personnel costs. The net loss for the quarter was $36 million, with a net loss per share of $3.00, an improvement from $5.53 in Q3 2019.